{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["VEGFR-2", "anticancer", "apoptosis", "immunomodulatory", "in silico studies", "nicotinamide"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35807326", "DateCompleted": {"Year": "2022", "Month": "07", "Day": "12"}, "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "06", "Day": "24"}], "Language": ["eng"], "ELocationID": ["4079", "10.3390/molecules27134079"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "27", "Issue": "13", "PubDate": {"Year": "2022", "Month": "Jun", "Day": "24"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.", "Abstract": {"AbstractText": ["VEGFR-2, the subtype receptor tyrosine kinase (RTK) responsible for angiogenesis, is expressed in various cancer cells. Thus, VEGFER-2 inhibition is an efficient approach for the discovery of new anticancer agents. Accordingly, a new set of nicotinamide derivatives were designed and synthesized to be VEGFR-2 inhibitors. The chemical structures were confirmed using IR, <sup>1</sup>H-NMR, and <sup>13</sup>C-NMR spectroscopy. The obtained compounds were examined for their anti-proliferative activities against the human cancer cell lines (HCT-116 and HepG2). VEGFR-2 inhibitory activities were determined for the titled compounds. Compound <b>8</b> exhibited the strongest anti-proliferative activities with IC<sub>50</sub> values of 5.4 and 7.1 \u00b5M against HCT-116 and HepG2, respectively. Interestingly, compound <b>8</b> was the most potent VEGFR-2 inhibitor with an IC<sub>50</sub> value of 77.02 nM (compare to sorafenib: IC<sub>50</sub> = 53.65 nM). Treatment of HCT-116 cells with compound <b>8</b> produced arrest of the cell cycle at the G0-G1 phase and a total apoptosis increase from 3.05 to 19.82%-6.5-fold in comparison to the negative control. In addition, compound <b>8</b> caused significant increases in the expression levels of caspase-8 (9.4-fold) and Bax (9.2-fold), and a significant decrease in the Bcl-2 expression level (3-fold). The effects of compound <b>8</b> on the levels of the immunomodulatory proteins (TNF-\u03b1 and IL-6) were examined. There was a marked decrease in the level of TNF-\u03b1 (92.37%) compared to the control (82.47%) and a non-significant reduction in the level of IL-6. In silico docking, molecular dynamics simulations, and MM-PBSA studies revealed the high affinity, the correct binding, and the optimum dynamics of compound 8 inside the active site of VEGFR-2. Finally, in silico ADMET and toxicity studies indicated acceptable values of drug-likeness. In conclusion, compound <b>8</b> has emerged as a promising anti-proliferative agent targeting VEGFR-2 with significant apoptotic and immunomodulatory effects."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": ["0000-0001-6996-4017"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt."}], "LastName": "Eldehna", "ForeName": "Wagdy M", "Initials": "WM"}, {"Identifier": ["0000-0003-4270-616X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Elwan", "ForeName": "Alaa", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Abdelaziz", "ForeName": "Abdelaziz S", "Initials": "AS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Mehany", "ForeName": "Ahmed B M", "Initials": "ABM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zoology Department, Faculty of Science (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Gobaara", "ForeName": "Ibraheem M M", "Initials": "IMM"}, {"Identifier": ["0000-0001-6489-6035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Bshra A", "Initials": "BA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry and Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}], "GrantList": [{"GrantID": "PNURSP2022R142", "Agency": "Princess Nourah bint Abdulrahman University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Interleukin-6"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Necrosis Factor-alpha"}, {"RegistryNumber": "25X51I8RD4", "NameOfSubstance": "Niacinamide"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": [], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Interleukin-6"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Niacinamide"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Tumor Necrosis Factor-alpha"}, {"QualifierName": [], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA A Cancer J. Clin. 2020;70:7\u201330. doi: 10.3322/caac.21590.", "ArticleIdList": ["10.3322/caac.21590", "31912902"]}, {"Citation": "Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021;71:209\u2013249. doi: 10.3322/caac.21660.", "ArticleIdList": ["10.3322/caac.21660", "33538338"]}, {"Citation": "Fabbro D., Parkinson D., Matter A. Protein tyrosine kinase inhibitors: New treatment modalities? Curr. Opin. Pharmacol. 2002;2:374\u2013381. doi: 10.1016/S1471-4892(02)00179-0.", "ArticleIdList": ["10.1016/S1471-4892(02)00179-0", "12127869"]}, {"Citation": "Abdallah A.E., Mabrouk R.R., Al Ward M.M.S., Eissa S.I., Elkaeed E.B., Mehany A.B., Abo-Saif M.A., El-Feky O.A., Alesawy M.S., El-Zahabi M.A. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. J. Enzym. Inhib. Med. Chem. 2022;37:573\u2013591. doi: 10.1080/14756366.2021.2017911.", "ArticleIdList": ["10.1080/14756366.2021.2017911", "PMC8757611", "35012403"]}, {"Citation": "Lugano R., Ramachandran M., Dimberg A. Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 2020;77:1745\u20131770. doi: 10.1007/s00018-019-03351-7.", "ArticleIdList": ["10.1007/s00018-019-03351-7", "PMC7190605", "31690961"]}, {"Citation": "Phillips C.M., Lima E.A., Woodall R.T., Brock A., Yankeelov T.E. A hybrid model of tumor growth and angiogenesis: In silico experiments. PLoS ONE. 2020;15:e0231137. doi: 10.1371/journal.pone.0231137.", "ArticleIdList": ["10.1371/journal.pone.0231137", "PMC7147760", "32275674"]}, {"Citation": "Patel H.M., Bari P., Karpoormath R., Noolvi M., Thapliyal N., Surana S., Jain P. Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening. RSC Adv. 2015;5:56724\u201356771. doi: 10.1039/C5RA05277G.", "ArticleIdList": ["10.1039/C5RA05277G"]}, {"Citation": "Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002;29:15\u201318. doi: 10.1053/sonc.2002.37263.", "ArticleIdList": ["10.1053/sonc.2002.37263", "12516034"]}, {"Citation": "Shibuya M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. J. Biochem. 2013;153:13\u201319. doi: 10.1093/jb/mvs136.", "ArticleIdList": ["10.1093/jb/mvs136", "PMC3528006", "23172303"]}, {"Citation": "Frezzetti D., Gallo M., Roma C., D\u2019Alessio A., Maiello M.R., Bevilacqua S., Normanno N., De Luca A. Vascular endothelial growth factor a regulates the secretion of different angiogenic factors in lung cancer cells. J. Cell. Physiol. 2016;231:1514\u20131521. doi: 10.1002/jcp.25243.", "ArticleIdList": ["10.1002/jcp.25243", "26542886"]}, {"Citation": "Stuttfeld E., Ballmer-Hofer K. Structure and function of VEGF receptors. IUBMB Life. 2009;61:915\u2013922. doi: 10.1002/iub.234.", "ArticleIdList": ["10.1002/iub.234", "19658168"]}, {"Citation": "Shi L., Zhou J., Wu J., Shen Y., Li X. Anti-angiogenic therapy: Strategies to develop potent VEGFR-2 tyrosine kinase inhibitors and future prospect. Curr. Med. Chem. 2016;23:1000\u20131040. doi: 10.2174/0929867323666160210130426.", "ArticleIdList": ["10.2174/0929867323666160210130426", "26860998"]}, {"Citation": "Shahin M.I., Abou El Ella D.A., Ismail N.S., Abouzid K.A. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold. Bioorganic Chem. 2014;56:16\u201326. doi: 10.1016/j.bioorg.2014.05.010.", "ArticleIdList": ["10.1016/j.bioorg.2014.05.010", "24922538"]}, {"Citation": "Zeidan M.A., Mostafa A.S., Gomaa R.M., Abou-Zeid L.A., El-Mesery M., Magda A.-A., Selim K.B. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. Eur. J. Med. Chem. 2019;168:315\u2013329. doi: 10.1016/j.ejmech.2019.02.050.", "ArticleIdList": ["10.1016/j.ejmech.2019.02.050", "30826508"]}, {"Citation": "Kassab A.E., Gedawy E.M., Hamed M.I., Doghish A.S., Hassan R.A. Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. J. Enzym. Inhib. Med. Chem. 2021;36:922\u2013939. doi: 10.1080/14756366.2021.1901089.", "ArticleIdList": ["10.1080/14756366.2021.1901089", "PMC8079033", "33896327"]}, {"Citation": "Pal M.K., Jaiswar S.P., Srivastav A.K., Goyal S., Dwivedi A., Verma A., Singh J., Pathak A.K., Sankhwar P.L., Ray R.S. Synergistic effect of piperine and paclitaxel on cell fate via cyt-c, Bax/Bcl-2-caspase-3 pathway in ovarian adenocarcinomas SKOV-3 cells. Eur. J. Pharmacol. 2016;791:751\u2013762. doi: 10.1016/j.ejphar.2016.10.019.", "ArticleIdList": ["10.1016/j.ejphar.2016.10.019", "27756602"]}, {"Citation": "Ling Y., Lu N., Gao Y., Chen Y., Wang S., Yang Y., Guo Q. Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res. 2009;29:411\u2013417.", "ArticleIdList": ["19331180"]}, {"Citation": "Alsaif N.A., Elwan A., Alanazi M.M., Obaidullah A.J., Alanazi W.A., Alasmari A.F., Albassam H., Mahdy H.A., Taghour M.S. Design, synthesis and molecular docking of new [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Mol. Divers. 2021;347:1\u201318. doi: 10.1007/s11030-021-10303-6.", "ArticleIdList": ["10.1007/s11030-021-10303-6", "34460053"]}, {"Citation": "Eissa I.H., El-Helby A.-G.A., Mahdy H.A., Khalifa M.M., Elnagar H.A., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M., ElSohly M.A. Discovery of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. Bioorganic Chem. 2020;105:104380. doi: 10.1016/j.bioorg.2020.104380.", "ArticleIdList": ["10.1016/j.bioorg.2020.104380", "33128967"]}, {"Citation": "El-Adl K., Ibrahim M.K., Khedr F., Abulkhair H.S., Eissa I.H. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies. Arch. Der Pharm. 2021;354:2000219. doi: 10.1002/ardp.202000219.", "ArticleIdList": ["10.1002/ardp.202000219", "33197080"]}, {"Citation": "El-Adl K., Sakr H.M., Yousef R.G., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M., ElSohly M.A., Abulkhair H.S., Eissa I.H. Discovery of new quinoxaline-2 (1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. Bioorganic Chem. 2021;114:105105. doi: 10.1016/j.bioorg.2021.105105.", "ArticleIdList": ["10.1016/j.bioorg.2021.105105", "34175720"]}, {"Citation": "Wang R., Liu H., You Y.-Y., Wang X.-Y., Lv B.-B., Cao L.-Q., Xue J.-Y., Xu Y.-G., Shi L. Discovery of novel VEGFR-2 inhibitors embedding 6, 7-dimethoxyquinazoline and diarylamide fragments. Bioorganic Med. Chem. Lett. 2021;36:127788. doi: 10.1016/j.bmcl.2021.127788.", "ArticleIdList": ["10.1016/j.bmcl.2021.127788", "33460739"]}, {"Citation": "Parmar D.R., Soni J.Y., Guduru R., Rayani R.H., Kusurkar R.V., Vala A.G., Talukdar S.N., Eissa I.H., Metwaly A.M., Khalil A., et al. Discovery of new anticancer thiourea-azetidine hybrids: Design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorganic Chem. 2021;115:105206. doi: 10.1016/j.bioorg.2021.105206.", "ArticleIdList": ["10.1016/j.bioorg.2021.105206", "34339975"]}, {"Citation": "Alanazi M.M., Eissa I.H., Alsaif N.A., Obaidullah A.J., Alanazi W.A., Alasmari A.F., Albassam H., Elkady H., Elwan A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J. Enzym. Inhib. Med. Chem. 2021;36:1760\u20131782. doi: 10.1080/14756366.2021.1956488.", "ArticleIdList": ["10.1080/14756366.2021.1956488", "PMC8344243", "34340610"]}, {"Citation": "Mohamed T.K., Batran R.Z., Elseginy S.A., Ali M.M., Mahmoud A.E. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Bioorganic Chem. 2019;85:253\u2013273. doi: 10.1016/j.bioorg.2018.12.040.", "ArticleIdList": ["10.1016/j.bioorg.2018.12.040", "30641320"]}, {"Citation": "Reddy V.G., Reddy T.S., Jadala C., Reddy M.S., Sultana F., Akunuri R., Bhargava S.K., Wlodkowic D., Srihari P., Kamal A. Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model. Eur. J. Med. Chem. 2019;182:111609. doi: 10.1016/j.ejmech.2019.111609.", "ArticleIdList": ["10.1016/j.ejmech.2019.111609", "31445229"]}, {"Citation": "El-Adl K., El-Helby A.-G.A., Sakr H., Elwan A. Design, synthesis, molecular docking and anti-proliferative evaluations of [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors. Bioorganic Chem. 2020;105:104399. doi: 10.1016/j.bioorg.2020.104399.", "ArticleIdList": ["10.1016/j.bioorg.2020.104399", "33113414"]}, {"Citation": "El-Adl K., El-Helby A.-G.A., Sakr H., Elwan A. [1, 2, 4] Triazolo [4, 3-a] quinoxaline and [1, 2, 4] triazolo [4, 3-a] quinoxaline-1-thiol-derived DNA intercalators: Design, synthesis, molecular docking, in silico ADMET profiles and anti-proliferative evaluations. New J. Chem. 2021;45:881\u2013897. doi: 10.1039/D0NJ02990D.", "ArticleIdList": ["10.1039/D0NJ02990D"]}, {"Citation": "Alsaif N.A., Dahab M.A., Alanazi M.M., Obaidullah A.J., Al-Mehizia A.A., Alanazi M.M., Aldawas S., Mahdy H.A., Elkady H. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. Bioorganic Chem. 2021;110:104807. doi: 10.1016/j.bioorg.2021.104807.", "ArticleIdList": ["10.1016/j.bioorg.2021.104807", "33721808"]}, {"Citation": "Alanazi M.M., Mahdy H.A., Alsaif N.A., Obiadullah A.J., Alkahtani H.M., Al-Mehizia A.A., Alsubaie S.M., Dahab M.A., Eissa I.H. New bis ([1, 2, 4] triazolo)[4, 3-a: 3\u2032, 4\u2032-c] quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Bioorganic Chem. 2021;112:104949. doi: 10.1016/j.bioorg.2021.104949.", "ArticleIdList": ["10.1016/j.bioorg.2021.104949", "34023640"]}, {"Citation": "Mahdy H.A., Ibrahim M.K., Metwaly A.M., Belal A., Mehany A.B., El-Gamal K.M., El-Sharkawy A., Elhendawy M.A., Radwan M.M., Elsohly M.A. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorganic Chem. 2020;94:103422. doi: 10.1016/j.bioorg.2019.103422.", "ArticleIdList": ["10.1016/j.bioorg.2019.103422", "31812261"]}, {"Citation": "Eissa I.H., Ibrahim M.K., Metwaly A.M., Belal A., Mehany A.B., Abdelhady A.A., Elhendawy M.A., Radwan M.M., ElSohly M.A., Mahdy H.A. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Bioorganic Chem. 2021;107:104532. doi: 10.1016/j.bioorg.2020.104532.", "ArticleIdList": ["10.1016/j.bioorg.2020.104532", "33334586"]}, {"Citation": "Eid A.M., Hawash M., Amer J., Jarrar A., Qadri S., Alnimer I., Sharaf A., Zalmoot R., Hammoudie O., Hameedi S. Synthesis and biological evaluation of novel isoxazole-amide analogues as anticancer and antioxidant agents. BioMed Res. Int. 2021;2021:6633297. doi: 10.1155/2021/6633297.", "ArticleIdList": ["10.1155/2021/6633297", "PMC7963892", "33763478"]}, {"Citation": "Hassan A., Badr M., Hassan H.A., Abdelhamid D., Abuo-Rahma G.E.D.A. Novel 4-(piperazin-1-yl) quinolin-2 (1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition. Bioorganic Med. Chem. 2021;40:116168. doi: 10.1016/j.bmc.2021.116168.", "ArticleIdList": ["10.1016/j.bmc.2021.116168", "33962153"]}, {"Citation": "El-Metwally S.A., Abou-El-Regal M.M., Eissa I.H., Mehany A.B., Mahdy H.A., Elkady H., Elwan A., Elkaeed E.B. Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorganic Chem. 2021;112:104947. doi: 10.1016/j.bioorg.2021.104947.", "ArticleIdList": ["10.1016/j.bioorg.2021.104947", "33964580"]}, {"Citation": "Zhong M., Li N., Qiu X., Ye Y., Chen H., Hua J., Yin P., Zhuang G. TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal cancer. Int. J. Biol. Sci. 2020;16:272. doi: 10.7150/ijbs.37906.", "ArticleIdList": ["10.7150/ijbs.37906", "PMC6949158", "31929755"]}, {"Citation": "Han L., Lin X., Yan Q., Gu C., Li M., Pan L., Meng Y., Zhao X., Liu S., Li A. PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells. Oncogene. 2022;41:1851\u20131865. doi: 10.1038/s41388-022-02197-x.", "ArticleIdList": ["10.1038/s41388-022-02197-x", "PMC8956508", "35140333"]}, {"Citation": "Pritchett J.C., Naesens L., Montoya J. Human Herpesviruses HHV-6A, HHV-6B & HHV-7. Elsevier; Amsterdam, The Netherlands: 2014. Treating HHV-6 infections: The laboratory efficacy and clinical use of ati-HHV-6 agents."}, {"Citation": "Indrayanto G., Putra G.S., Suhud F. Validation of in-vitro bioassay methods: Application in herbal drug research. Profiles Drug Subst. Excip. Relat. Methodol. 2021;46:273\u2013307.", "ArticleIdList": ["33461699"]}, {"Citation": "Pucci B., Kasten M., Giordano A. Cell cycle and apoptosis. Neoplasia. 2000;2:291\u2013299. doi: 10.1038/sj.neo.7900101.", "ArticleIdList": ["10.1038/sj.neo.7900101", "PMC1550296", "11005563"]}, {"Citation": "Riccardi C., Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 2006;1:1458\u20131461. doi: 10.1038/nprot.2006.238.", "ArticleIdList": ["10.1038/nprot.2006.238", "17406435"]}, {"Citation": "Vermes I., Haanen C., Steffens-Nakken H., Reutellingsperger C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J. Immunol. Methods. 1995;184:39\u201351. doi: 10.1016/0022-1759(95)00072-I.", "ArticleIdList": ["10.1016/0022-1759(95)00072-I", "7622868"]}, {"Citation": "Sobhy M.K., Mowafy S., Lasheen D.S., Farag N.A., Abouzid K.A. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation. Bioorganic Chem. 2019;89:102988. doi: 10.1016/j.bioorg.2019.102988.", "ArticleIdList": ["10.1016/j.bioorg.2019.102988", "31146197"]}, {"Citation": "Mena-Ulecia K., Tiznado W., Caballero J. Study of the differential activity of thrombin inhibitors using docking, QSAR, molecular dynamics, and MM-GBSA. PLoS ONE. 2015;10:e0142774. doi: 10.1371/journal.pone.0142774.", "ArticleIdList": ["10.1371/journal.pone.0142774", "PMC4657979", "26599107"]}, {"Citation": "Elkady H., Elwan A., El-Mahdy H.A., Doghish A.S., Ismail A., Taghour M.S., Elkaeed E.B., Eissa I.H., Dahab M.A., Mahdy H.A., et al. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:397\u2013410. doi: 10.1080/14756366.2021.2015343.", "ArticleIdList": ["10.1080/14756366.2021.2015343", "PMC8725875", "34961427"]}, {"Citation": "Alanazi M.M., Elwan A., Alsaif N.A., Obaidullah A.J., Alkahtani H.M., Al-Mehizia A.A., Alsubaie S.M., Taghour M.S., Eissa I.H. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: Design, synthesis, and in silico studies. J. Enzym. Inhib. Med. Chem. 2021;36:1732\u20131750. doi: 10.1080/14756366.2021.1945591.", "ArticleIdList": ["10.1080/14756366.2021.1945591", "PMC8330740", "34325596"]}, {"Citation": "Yousef R.G., Sakr H.M., Eissa I.H., Mehany A.B., Metwaly A.M., Elhendawy M.A., Radwan M.M., ElSohly M.A., Abulkhair H.S., El-Adl K. New quinoxaline-2 (1 H)-ones as potential VEGFR-2 inhibitors: Design, synthesis, molecular docking, ADMET profile and anti-proliferative evaluations. New J. Chem. 2021;45:16949\u201316964. doi: 10.1039/D1NJ02509K.", "ArticleIdList": ["10.1039/D1NJ02509K", "34175720"]}, {"Citation": "Egan W.J., Merz K.M., Baldwin J.J. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 2000;43:3867\u20133877. doi: 10.1021/jm000292e.", "ArticleIdList": ["10.1021/jm000292e", "11052792"]}, {"Citation": "Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002;45:2615\u20132623. doi: 10.1021/jm020017n.", "ArticleIdList": ["10.1021/jm020017n", "12036371"]}, {"Citation": "Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 1997;23:3\u201325. doi: 10.1016/S0169-409X(96)00423-1.", "ArticleIdList": ["10.1016/S0169-409X(96)00423-1", "11259830"]}, {"Citation": "Sousa S.F., Fernandes P.A., Ramos M.J. Protein\u2013ligand docking: Current status and future challenges. Proteins Struct. Funct. Bioinform. 2006;65:15\u201326. doi: 10.1002/prot.21082.", "ArticleIdList": ["10.1002/prot.21082", "16862531"]}, {"Citation": "Hollingsworth S.A., Dror R.O. Molecular dynamics simulation for all. Neuron. 2018;99:1129\u20131143. doi: 10.1016/j.neuron.2018.08.011.", "ArticleIdList": ["10.1016/j.neuron.2018.08.011", "PMC6209097", "30236283"]}, {"Citation": "Hansson T., Oostenbrink C., van Gunsteren W. Molecular dynamics simulations. Curr. Opin. Struct. Biol. 2002;12:190\u2013196. doi: 10.1016/S0959-440X(02)00308-1.", "ArticleIdList": ["10.1016/S0959-440X(02)00308-1", "11959496"]}, {"Citation": "Durrant J.D., McCammon J.A. Molecular dynamics simulations and drug discovery. BMC Biol. 2011;9:71. doi: 10.1186/1741-7007-9-71.", "ArticleIdList": ["10.1186/1741-7007-9-71", "PMC3203851", "22035460"]}, {"Citation": "Genheden S., Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 2015;10:449\u2013461. doi: 10.1517/17460441.2015.1032936.", "ArticleIdList": ["10.1517/17460441.2015.1032936", "PMC4487606", "25835573"]}, {"Citation": "Ran F., Li W., Qin Y., Yu T., Liu Z., Zhou M., Liu C., Qiao T., Li X., Yousef R.G., et al. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation. Oxidative Med. Cell. Longev. 2021;2021:8321400. doi: 10.1155/2021/8321400.", "ArticleIdList": ["10.1155/2021/8321400", "PMC8568530", "34745424"]}, {"Citation": "Chaitra G., Rohini R. Synthesis and biological activities of [1, 3]-oxazine derivatives. Der Pharma Chem. 2018;10:96\u2013101."}, {"Citation": "Eldehna W.M., Al-Rashood S.T., Al-Warhi T., Eskandrani R.O., Alharbi A., El Kerdawy A.M. Novel oxindole/benzofuran hybrids as potential dual CDK2/GSK-3\u03b2 inhibitors targeting breast cancer: Design, synthesis, biological evaluation, and in silico studies. J. Enzym. Inhib. Med. Chem. 2021;36:270\u2013285. doi: 10.1080/14756366.2020.1862101.", "ArticleIdList": ["10.1080/14756366.2020.1862101", "PMC7751407", "33327806"]}, {"Citation": "Al-Sanea M.M., Al-Ansary G.H., Elsayed Z.M., Maklad R.M., Elkaeed E.B., Abdelgawad M.A., Bukhari S.N.A., Abdel-Aziz M.M., Suliman H., Eldehna W.M., et al. Development of 3-methyl/3-(morpholinomethyl) benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells. J. Enzym. Inhib. Med. Chem. 2021;36:987\u2013999. doi: 10.1080/14756366.2021.1915302.", "ArticleIdList": ["10.1080/14756366.2021.1915302", "PMC8128204", "33985397"]}, {"Citation": "Abou-Seri S.M., Eldehna W.M., Ali M.M., Abou El Ella D.A. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. Eur. J. Med. Chem. 2016;107:165\u2013179. doi: 10.1016/j.ejmech.2015.10.053.", "ArticleIdList": ["10.1016/j.ejmech.2015.10.053", "26590508"]}, {"Citation": "Kim K.H., Sederstrom J.M. Assaying cell cycle status using flow cytometry. Curr. Protoc. Mol. Biol. 2015;111:28.6.1\u201328.6.11. doi: 10.1002/0471142727.mb2806s111.", "ArticleIdList": ["10.1002/0471142727.mb2806s111", "PMC4516267", "26131851"]}, {"Citation": "Lo K.K.-W., Lee T.K.-M., Lau J.S.-Y., Poon W.-L., Cheng S.-H. Luminescent biological probes derived from ruthenium (II) estradiol polypyridine complexes. Inorg. Chem. 2008;47:200\u2013208. doi: 10.1021/ic701735q.", "ArticleIdList": ["10.1021/ic701735q", "18067284"]}, {"Citation": "Sabt A., Abdelhafez O.M., El-Haggar R.S., Madkour H.M., Eldehna W.M., El-Khrisy E.E.-D.A., Abdel-Rahman M.A., Rashed L.A. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: Synthesis, in vitro biological evaluation, and QSAR studies. J. Enzym. Inhib. Med. Chem. 2018;33:1095\u20131107. doi: 10.1080/14756366.2018.1477137.", "ArticleIdList": ["10.1080/14756366.2018.1477137", "PMC6022226", "29944015"]}, {"Citation": "Hawash M., Qneibi M., Jaradat N., Abualhasan M., Amer J., Amer E.-H., Ibraheem T., Hindieh S., Tarazi S., Sobuh S., et al. The impact of filtered water-pipe smoke on healthy versus cancer cells and their neurodegenerative role on AMPA receptor. Drug Chem. Toxicol. 2021. pp. 1\u20139. online ahead of print .", "ArticleIdList": ["10.1080/01480545.2021.1935397", "34121557"]}, {"Citation": "Balah A., Ezzat O., Akool E.-S. Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-\u03b2/Smad signaling pathway in rat liver. Int. Immunopharmacol. 2018;65:493\u2013502. doi: 10.1016/j.intimp.2018.09.033.", "ArticleIdList": ["10.1016/j.intimp.2018.09.033", "30391882"]}, {"Citation": "Aborehab N.M., Elnagar M.R., Waly N.E. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J. Biochem. Mol. Toxicol. 2020;35:e22638. doi: 10.1002/jbt.22638.", "ArticleIdList": ["10.1002/jbt.22638", "33002289"]}, {"Citation": "Elnagar M.R., Walls A.B., Helal G.K., Hamada F.M., Thomsen M.S., Jensen A.A. Functional characterization of \u03b17 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. Eur. J. Pharmacol. 2018;826:106\u2013113. doi: 10.1016/j.ejphar.2018.02.047.", "ArticleIdList": ["10.1016/j.ejphar.2018.02.047", "29501870"]}, {"Citation": "Yousef R.G., Ibrahim A., Khalifa M.M., Eldehna W.M., Gobaara I.M., Mehany A.B., Elkaeed E.B., Alsfouk A.A., Metwaly A.M. Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: Virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies. J. Enzym. Inhib. Med. Chem. 2022;37:1389\u20131403. doi: 10.1080/14756366.2022.2070744.", "ArticleIdList": ["10.1080/14756366.2022.2070744", "PMC9116259", "35577416"]}, {"Citation": "Jo S., Kim T., Iyer V.G., Im W. CHARMM-GUI: A web-based graphical user interface for CHARMM. J. Comput. Chem. 2008;29:1859\u20131865. doi: 10.1002/jcc.20945.", "ArticleIdList": ["10.1002/jcc.20945", "18351591"]}, {"Citation": "Brooks B., Brooks C., Mackerell A., Nilsson L., Petrella R., Roux B., Won Y., Archontis G., Bartels C., Boresch S., et al. CHARMM: The biomolecular simulation program. J. Comput. Chem. 2009;30:1545\u20131614. doi: 10.1002/jcc.21287.", "ArticleIdList": ["10.1002/jcc.21287", "PMC2810661", "19444816"]}, {"Citation": "Lee J., Cheng X., Swails J.M., Yeom M.S., Eastman P.K., Lemkul J., Wei S., Buckner J., Jeong J.C., Qi Y., et al. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. J. Chem. Theory Comput. 2015;12:405\u2013413. doi: 10.1021/acs.jctc.5b00935.", "ArticleIdList": ["10.1021/acs.jctc.5b00935", "PMC4712441", "26631602"]}, {"Citation": "Best R., Zhu X., Shim J., Lopes P., Mittal J., Feig M. and MacKerell, A. Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone \u03d5, \u03c8 and Side-Chain \u03c71 and \u03c72 Dihedral Angles. J. Chem. Theory Comput. 2012;8:3257\u20133273. doi: 10.1021/ct300400x.", "ArticleIdList": ["10.1021/ct300400x", "PMC3549273", "23341755"]}, {"Citation": "Phillips J., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., Chipot C., Skeel R., Kal\u00e9 L., Schulten K. Scalable molecular dynamics with NAMD. J. Comput. Chem. 2005;26:1781\u20131802. doi: 10.1002/jcc.20289.", "ArticleIdList": ["10.1002/jcc.20289", "PMC2486339", "16222654"]}, {"Citation": "Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983;79:926\u2013935. doi: 10.1063/1.445869.", "ArticleIdList": ["10.1063/1.445869"]}, {"Citation": "Yu W., He X., Vanommeslaeghe K., MacKerell A.D. Extension of the CHARMM general force field to sulfonyl-containing compounds and its utility in biomolecular simulations. J. Comput. Chem. 2012;33:2451\u20132468. doi: 10.1002/jcc.23067.", "ArticleIdList": ["10.1002/jcc.23067", "PMC3477297", "22821581"]}, {"Citation": "Nos\u00e9 S., Klein M. Constant pressure molecular dynamics for molecular systems. Mol. Phys. 1983;50:1055\u20131076. doi: 10.1080/00268978300102851.", "ArticleIdList": ["10.1080/00268978300102851"]}, {"Citation": "Nos\u00e9 S. A molecular dynamics method for simulations in the canonical ensemble. Mol. Phys. 1984;52:255\u2013268. doi: 10.1080/00268978400101201.", "ArticleIdList": ["10.1080/00268978400101201"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "5", "Day": "4"}, {"Year": "2022", "Month": "6", "Day": "15"}, {"Year": "2022", "Month": "6", "Day": "20"}, {"Year": "2022", "Month": "7", "Day": "9", "Hour": "1", "Minute": "18"}, {"Year": "2022", "Month": "7", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "7", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "6", "Day": "24"}], "PublicationStatus": "epublish", "ArticleIdList": ["35807326", "PMC9268560", "10.3390/molecules27134079", "molecules27134079"]}}], "PubmedBookArticle": []}